{"id":"W4388182377","doi":"10.1016/j.jacadv.2023.100675","title":"Lipoprotein(a) and Benefit of Antiplatelet Therapy","year":2023,"lang":"en","type":"article","venue":"JACC Advances","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; St. Jude Medical; CytoSorbents Europe; Silence Therapeutics; Intas Pharmaceuticals; Idorsia Pharmaceuticals; Assistance publique-Hôpitaux de Paris; Daiichi-Sankyo; Zora Biosciences; Belvoir Media Group; Novo Nordisk; MyoKardia; ARCA Biopharma; Regado Biosciences; Medicines Company; AstraZeneca; Amarin Corporation; Ionis Pharmaceuticals; Ironwood Pharmaceuticals, Incorporated; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Alnylam Pharmaceuticals; Duke Clinical Research Institute; Eisai; FibroGen; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bristol-Myers Squibb; Cleveland Clinic; HLS Therapeutics; GlaxoSmithKline; Quest Diagnostics; Abbott Laboratories; CSL Behring; Eli Lilly and Company; Moderna; Pfizer; American Heart Association; Intarcia Therapeutics; AstraZeneca Mölndal; Amgen; Abiomed; Sanofi; National Institutes of Health; Regeneron Pharmaceuticals","keywords":"Lipoprotein(a); Medicine; Lipoprotein; Cardiology; Intensive care medicine; Internal medicine; Cholesterol","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001201937,0.0001024044,0.0002928013,0.00008179554,0.00004860474,0.00000667204,0.00004751271,0.00004579222,0.00006450549],"category_scores_gemma":[0.00001716731,0.00007862337,0.0001393889,0.0002639925,0.00008831513,0.0001151839,0.00002059142,0.000055863,0.00001928591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00000370217,"about_ca_system_score_gemma":0.00001269777,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007706159,"about_ca_topic_score_gemma":0.000001296197,"domain_scores_codex":[0.9993098,0.00001048967,0.0001420757,0.0001792586,0.0002026892,0.0001557187],"domain_scores_gemma":[0.9996027,0.00003738072,0.00004808867,0.0002006888,0.00004450984,0.00006660425],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0006350185,0.00006481302,0.01848889,0.0001483602,0.0003015712,0.0001262637,0.0001513736,0.00003738548,0.006565269,0.0005355604,0.0001490452,0.9727964],"study_design_scores_gemma":[0.01141529,0.001444427,0.5052171,0.0004934088,0.0002071781,0.0003701104,0.001190905,0.0002397447,0.1385757,0.01805572,0.3221555,0.0006349095],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9628478,0.03535022,0.00005576063,0.0001736303,0.00006816746,0.0002346644,0.00001007761,0.0001053508,0.001154365],"genre_scores_gemma":[0.9485763,0.05029619,0.0002497085,0.0001260985,0.0001097076,0.0000163503,0.00001828686,0.00001707364,0.000590326],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9721615,"threshold_uncertainty_score":0.3206168,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01441820122523524,"score_gpt":0.2766879377190152,"score_spread":0.2622697364937799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}